ArticleRespirology case reports2026
Persistent SARS-CoV-2 RNA Positivity in a Chronic Lymphocytic Leukaemia Patient for 127 Days After Disease Onset: A Case Report.
Article in Respirology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic lymphocytic leukaemia (CLL) is characterised by profound immune dysfunction, increasing susceptibility to severe and persistent infections such as COVID-19. Our case report presents a 69-year-old woman with CLL who exhibited a prolonged duration of SARS-CoV-2 RT-PCR positivity-127 days-despite receiving standard therapies including dexamethasone and remdesivir. The patient, previously on maintenance ibrutinib, presented with fever and ground-glass opacities on CT scan and laboratory findings revealed marked lymphocytosis, elevated inflammatory markers and hepatic and renal dysfunction. Persistent viral shedding was attributed to CLL-associated hypogammaglobulinemia and chemotherapy-induced immunosuppression, resulting in impaired antibody response and eventual fatal hypoxemia. This case underscores the challenges of managing COVID-19 in CLL patients and highlights the need for individualised treatment strategies, including consideration of monoclonal antibodies and immunoglobulin replacement, to address prolonged viral replication and improve clinical outcomes in this vulnerable population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.